"uuid:ID","name","text","identifier","label","id","description","instanceType"
"4cf0f644-7b1c-4b6b-a831-915af29981b8","Age Criteria","Subjects shall be between [min_age] and [max_age]","1","","EligibilityCriterion_1","The study age criterion","EligibilityCriterion"
"adcb84ec-1260-4aa5-892e-94a856b576cd","Pop Criteria","[StudyPopulation] as defined by the NINCDS and the ADRDA guidelines (Attachment LZZT.7)","2","","EligibilityCriterion_2","The study population criterion","EligibilityCriterion"
"05017edd-b792-4789-90a2-9f16597b3273","Diag Criteria","[Activity1] score of 10 to 23","3","","EligibilityCriterion_3","The study diagnosis criterion","EligibilityCriterion"
"2807852b-4122-4f4a-80fe-c88096809dbe","Previous Criteria","Persons who have previously completed or withdrawn from this study or any other study investigating xanomeline TTS or the oral formulation of xanomeline.","9","","EligibilityCriterion_4","The previous xanomeline TTS criterion","EligibilityCriterion"
